Stefan Fruehauf
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Stefan Fruehauf has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Annika Kurreck
Charité-Universitätsmedizin Berlin 9 Department of Hematology, Oncology, and Cancer Immunology Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
27 shared publications - Arndt Stahler
Department of Hematology, Oncology and Cancer Immunology (CCM), Charité - Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin and Humboldt-Universitaet zu Berlin, Berlin, Germany
27 shared publications - Dominik Paul Modest
Department of Hematology, Oncology, and Cancer Immunology (CVK/CCM), Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
27 shared publications - Lothar Müller
Oncology Practice UnterEms, Leer, Germany
27 shared publications - Sebastian Stintzing
Department of Hematology, Oncology and Cancer Immunology, Charité—Universitaetsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
27 shared publications - Stefan Kasper
Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany
27 shared publications
Latest Publications
- 5 January 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (5) , 938-946
Deep Learning–Derived Sarcopenia Marker Predicts Benefit from Anti-EGFR Therapy in Patients with RAS Wild-type Metastatic Colorectal Cancer
Purpose: The benefit of treatment intensification in metastatic colorectal cancer (mCRC) may be influenced by host-related factors that are not accounted for in clinical trials or standard care. We investigated the prognostic and predictive value of the muscle/bone ratio (MBR), a sarcopenia marker automatically derived from computed tomography (CT) images, in patients with mCRC from the prospective PanaMa study and a real-world validation cohort. Experimental Design: PanaMa (AIO KRK 0212; NCT01991873) randomized patients with RAS wild-type mCRC, following induction therapy, to maintenance therapy with fluorouracil and folinic acid (FU/FA) with or without panitumumab (Pmab). MBR was automatically calculated from baseline CT images using a validated deep learning model, and patients were stratified by MBR tertiles. Associations with progression-free survival (PFS) and overall survival (OS) were studied using Kaplan–Meier and Cox regression analyses. A retrospective real-world cohort of patients with mCRC treated with cetuximab was used for validation. Results: Premaintenance CT images were available for 189 of 248 randomized patients (76.2%) from PanaMa. In patients receiving FU/FA + Pmab, high MBR was associated with longer PFS [HR, 0.43; 95% confidence interval (CI), 0.25–0.73; P = 0.002] and OS (HR, 0.41; 95% CI, 0.21–0.77; P = 0.006), whereas no association was observed in patients receiving FU/FA alone. Pmab provided a PFS benefit only in patients with high MBR (HR, 0.42; 95% CI, 0.24–0.73; P = 0.002). The association of high MBR with superior PFS (P = 0.002) and OS (P < 0.001) was confirmed in the real-world cohort. Conclusions: The benefit of anti-EGFR therapy in mCRC is confined to patients with a high MBR. Automated sarcopenia assessment holds promise for personalized treatment intensification in mCRC.
- 5 January 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (5) , 938-946
Deep Learning–Derived Sarcopenia Marker Predicts Benefit from Anti-EGFR Therapy in Patients with RAS Wild-type Metastatic Colorectal Cancer
Purpose: The benefit of treatment intensification in metastatic colorectal cancer (mCRC) may be influenced by host-related factors that are not accounted for in clinical trials or standard care. We investigated the prognostic and predictive value of the muscle/bone ratio (MBR), a sarcopenia marker automatically derived from computed tomography (CT) images, in patients with mCRC from the prospective PanaMa study and a real-world validation cohort. Experimental Design: PanaMa (AIO KRK 0212; NCT01991873) randomized patients with RAS wild-type mCRC, following induction therapy, to maintenance therapy with fluorouracil and folinic acid (FU/FA) with or without panitumumab (Pmab). MBR was automatically calculated from baseline CT images using a validated deep learning model, and patients were stratified by MBR tertiles. Associations with progression-free survival (PFS) and overall survival (OS) were studied using Kaplan–Meier and Cox regression analyses. A retrospective real-world cohort of patients with mCRC treated with cetuximab was used for validation. Results: Premaintenance CT images were available for 189 of 248 randomized patients (76.2%) from PanaMa. In patients receiving FU/FA + Pmab, high MBR was associated with longer PFS [HR, 0.43; 95% confidence interval (CI), 0.25–0.73; P = 0.002] and OS (HR, 0.41; 95% CI, 0.21–0.77; P = 0.006), whereas no association was observed in patients receiving FU/FA alone. Pmab provided a PFS benefit only in patients with high MBR (HR, 0.42; 95% CI, 0.24–0.73; P = 0.002). The association of high MBR with superior PFS (P = 0.002) and OS (P < 0.001) was confirmed in the real-world cohort. Conclusions: The benefit of anti-EGFR therapy in mCRC is confined to patients with a high MBR. Automated sarcopenia assessment holds promise for personalized treatment intensification in mCRC.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for RAS wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Overview of antibodies used for staining and cutoffs in TMA analysis.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for RAS wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Overview of antibodies used for staining and cutoffs in TMA analysis.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for RAS wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Analysis of overall survival within the maintenance therapy set by high/low immune expression, tumor region and treatment arm.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for RAS wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Analysis of overall survival within the maintenance therapy set by high/low immune expression, tumor region and treatment arm.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for RAS wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Risk analysis of Overall Response Rates in the epithelial tumor of tumor center and invasive margin in the Maintenance set by treatment arm.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for RAS wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Risk analysis of Overall Response Rates in the epithelial tumor of tumor center and invasive margin in the Maintenance set by treatment arm.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S11 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for RAS wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
P, Odds Ratios and 95% Confidence Intervals regarding ORR of immunoexpression in the epithelial tumor in the tumor center and the invasive margin after exclusion of cases with BRAF V600E and MSI – Maintenance Set.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S11 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for RAS wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
P, Odds Ratios and 95% Confidence Intervals regarding ORR of immunoexpression in the epithelial tumor in the tumor center and the invasive margin after exclusion of cases with BRAF V600E and MSI – Maintenance Set.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for RAS wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Confidence intervals, medians and P of IHC measurements. Paired-sampled t-test of stromal and epithelial immune infiltration in each tumor region.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for RAS wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Confidence intervals, medians and P of IHC measurements. Paired-sampled t-test of stromal and epithelial immune infiltration in each tumor region.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for RAS wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Risk analysis of Overall Response Rates in the Induction set.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for RAS wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Risk analysis of Overall Response Rates in the Induction set.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S12 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for RAS wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
P, Hazard Ratios and 95% Confidence Intervals regarding PFS of immunoexpression after exclusion of cases with BRAF V600E and MSI – Maintenance Set.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S12 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for RAS wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
P, Hazard Ratios and 95% Confidence Intervals regarding PFS of immunoexpression after exclusion of cases with BRAF V600E and MSI – Maintenance Set.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Data from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for RAS wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Purpose:Tumor immune cell infiltration patterns in the tumor microenvironment serve as prognostic biomarkers in metastatic colorectal cancer. This study analyzed the spatially resolved tumor immune microenvironment for prognostic and predictive impact in patients with RAS wild-type metastatic colorectal cancer receiving 5-fluoruracil/folinic acid ± panitumumab (Pmab) maintenance after Pmab + fluorouracil, folinic acid, and oxaliplatin induction (PanaMa AIO KRK0212; NCT01991873).Patients and Methods:Twelve immune parameters (lymphocyte markers: CD3, CD8, CD45RO, FOXP3, CD20, granzyme B, and perforin; immune checkpoints: PD-1, PD-L1, IDO1, and LAG3; and monocyte marker CD163) were quantified in spatially resolved tumor and stroma regions [invasive-margin (Inv) and center (Cen)] on tissue microarrays from available surgical resections using digital pathology. Prognostic and predictive associations were assessed using percentile cutoffs, immunoscore (IS), PD-L1 combined positive score, and an immunoactivation score (IAS). The median progression-free (PFS) and overall survival (OS) were estimated by the Kaplan–Meier method, log rank test, and Cox regression.Results:In 194 patients, low CD163 and high PD-1 in the tumor center were independent prognostic factors for prolonged PFS, whereas high central LAG3 was associated with improved OS. Pmab maintenance conferred PFS benefit in patients with low CD3InvStr, CD8Inv, LAG3CenTum, CD163CenTum, and IS and high CD45ROCen. CD45ROCen high and LAG3Cen low also predicted OS benefit. A positive IAS (≥2 predictive markers) identified patients deriving significant PFS (HR = 0.50; 95% confidence interval, 0.32–0.76; P < 0.001) and OS (HR = 0.54; 95% confidence interval, 0.33–0.86; P = 0.009) benefit from Pmab.Conclusions:Immune microenvironment factors, including CD3, CD8, CD163, LAG3, CD45RO, IS, and IAS, predict benefit from Pmab maintenance, suggesting immune activation as a key component of anti-EGFR efficacy.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for RAS wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Purpose:Tumor immune cell infiltration patterns in the tumor microenvironment serve as prognostic biomarkers in metastatic colorectal cancer. This study analyzed the spatially resolved tumor immune microenvironment for prognostic and predictive impact in patients with RAS wild-type metastatic colorectal cancer receiving 5-fluoruracil/folinic acid ± panitumumab (Pmab) maintenance after Pmab + fluorouracil, folinic acid, and oxaliplatin induction (PanaMa AIO KRK0212; NCT01991873).Patients and Methods:Twelve immune parameters (lymphocyte markers: CD3, CD8, CD45RO, FOXP3, CD20, granzyme B, and perforin; immune checkpoints: PD-1, PD-L1, IDO1, and LAG3; and monocyte marker CD163) were quantified in spatially resolved tumor and stroma regions [invasive-margin (Inv) and center (Cen)] on tissue microarrays from available surgical resections using digital pathology. Prognostic and predictive associations were assessed using percentile cutoffs, immunoscore (IS), PD-L1 combined positive score, and an immunoactivation score (IAS). The median progression-free (PFS) and overall survival (OS) were estimated by the Kaplan–Meier method, log rank test, and Cox regression.Results:In 194 patients, low CD163 and high PD-1 in the tumor center were independent prognostic factors for prolonged PFS, whereas high central LAG3 was associated with improved OS. Pmab maintenance conferred PFS benefit in patients with low CD3InvStr, CD8Inv, LAG3CenTum, CD163CenTum, and IS and high CD45ROCen. CD45ROCen high and LAG3Cen low also predicted OS benefit. A positive IAS (≥2 predictive markers) identified patients deriving significant PFS (HR = 0.50; 95% confidence interval, 0.32–0.76; P < 0.001) and OS (HR = 0.54; 95% confidence interval, 0.33–0.86; P = 0.009) benefit from Pmab.Conclusions:Immune microenvironment factors, including CD3, CD8, CD163, LAG3, CD45RO, IS, and IAS, predict benefit from Pmab maintenance, suggesting immune activation as a key component of anti-EGFR efficacy.